Protagonist Therapeutics rises on quarterly profit beat

Protagonist Therapeutics

21/02/2025 14:54

** Drug developer Protagonist Therapeutics'  PTGX.O  shares
rise 3.1% to $39.68
    ** Company posts Q4 adj profit of $1.98 per share, beating
analysts' estimates of 32 cents per share, according to data
compiled by LSEG 
     ** The company got a $165 million milestone payment during
Q4 2024 after it entered into a license and collaboration
agreement with Johnson & Johnson  JNJ.N  for skin disease drug
icotrokinra in November 2024
    ** PGTX expects to release late-stage study results of blood
cancer treatment rusfertide in collaboration with Takeda
Pharmaceutical  4502.T  in March 2025 
    ** In the last 12 months, PTGX has risen 41.4% 

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))